CTA 056 possesses high inhibitory effects toward interleukin-2-inducible T-cell kinase (Itk), Bruton’s tyrosine kinase and endothelial and epithelial tyrosine kinase. Also, it targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma.
